Share on social media
08 February 2018
The IP landscape for life sciences companies is more unpredictable than it has been for many years. In Europe, there is Brexit and the unknown future of the proposed Unified Patent Court (UPC) system. Meanwhile, in the United States, the inter partes review regime and eligibility issues have raised major concerns. All of this is before you consider the latest Hatch-Waxman developments, the rise of biosimilars, second medical use patents updates and supplementary protection certificate controversies.
Koen Vanhalst will be staying up to date with navigating current uncertainties to craft effective protection and value creation strategies in order to thrive during these unpredictable times.
IAM’s second annual Pharma and Biotech IP Summit is held in London on Thursday February 8, 2018